Akebia 10-Q: $36.9M Q3 Revenue, $14.4M Net Loss, and a 2027 Vafseo Revenue Warning
AKBA is trading near its 52-week low of $0.542 (4.1% below the low).
Summary
Akebia's Q3 10-Q confirms $36.9 million of revenue and a $14.4 million net loss, and adds that Vafseo revenue is expected to drop significantly in 2027 when TDAPA ends, with the two-year runway contingent on refinancing the BlackRock term loan.
Key Events · Earnings and Guidance · AKBA
-
Q3 Revenue Falls 37% on Auryxia Generics
Total revenue was $36.9 million versus $58.8 million a year earlier; Auryxia net product revenue dropped to $20.0 million from $42.5 million while Vafseo was roughly flat at $14.8 million versus $14.3 million.
-
Net Loss of $14.4 Million
The quarter swung to a $14.4 million net loss from $0.5 million of net income a year earlier, including a $1.3 million restructuring charge; the nine-month net loss was $32.3 million.
-
2027 Vafseo Revenue Expected to Drop Sharply
TDAPA reimbursement ends December 31, 2026, and Akebia expects to price Vafseo within the ESA range in 2027, so revenue is expected to decrease significantly versus 2026 despite higher unit volume.
-
Runway Contingent on Refinancing BlackRock Debt
Cash was $159.3 million at September 30, 2026; the stated two-year runway assumes refinancing the term loan, whose interest-only period ends December 31, 2026 and which has $50.6 million of principal due in 2027.
Analysis · AKBA · Life Sciences
The headline numbers match this morning's earnings release, but the full 10-Q carries two things the press release did not spell out. First, Akebia expects Vafseo revenue to fall significantly in 2027 versus 2026: the TDAPA add-on payment ends December 31, 2026, and the company plans to reprice Vafseo toward the much lower ESA range even though unit volumes should rise. Second, the stated two-year cash runway is explicitly contingent on refinancing the BlackRock term loan, whose interest-only period ends December 31, 2026 and which carries $50.6 million of principal due in 2027. With $159.3 million of cash, a $32.3 million nine-month net loss, and a Nasdaq bid-price deficiency already disclosed, the equity story now hinges on the 2027 Vafseo pricing reset and the debt refinancing rather than on the quarter itself.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AKBA was trading at $0.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $192.5M. The 52-week trading range was $0.54 to $2.15. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.